Biologic facts
BrandBeovu (Brolucizumab)
No biosimilar to Beovu is licensed. The 12-year reference exclusivity date of 10/2031 is an estimate from first approval; the Purple Book does not list patents, which can protect a biologic longer.
Beovu was first approved by the FDA in 2019; the application holder is Novartis Pharmaceuticals Corporation.
Holder Novartis Pharmaceuticals CorporationApproved 2019
01Exclusivity
When biosimilar competition can legally begin. The Purple Book lists reference exclusivity but not patents, which can protect a biologic longer.
- Patents
- Not listed in the Purple Book Purple Book
- Reference exclusivity
- 10/203112-year estimate from first approval Purple Book
02Competition
- Biosimilars
- No biosimilar approved Purple Book
Every makerEach licensed product and biosimilar maker.
PrescribersWho prescribes it, from Medicare data.
Spend and safetyMedicare Part B spend and safety reports.
Available in the full Beovu profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
04Product
- Application holder
- Novartis Pharmaceuticals Corporation Purple Book
- First approved
- 2019 Purple Book
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.